Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

CD79 Expression Is Associated with Cell-of-Origin and Outcome in Diffuse Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1760.

https://doi.org/10.1182/blood-2023-172972

Published: 2023

Journal Articles

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 3026.

https://doi.org/10.1182/blood-2023-181309

Published: 2023

Journal Articles

Single Cell Multi Omics and Spatial Analysis Reveals Plasmablast Signature Malignant Cells As a Key of Intratumor Heterogeneity in Primary Central Nervous System Lymphoma

Blood (2023) 142 (Supplement 1): 2998.

https://doi.org/10.1182/blood-2023-174410

Published: 2023

Journal Articles

Clinical Impact of Cell-of-Origin and Double-Hit Signature of DLBCL in Japan

Blood (2022) 140 (Supplement 1): 6421–6423.

https://doi.org/10.1182/blood-2022-157702

Published: 2022

Journal Articles

Impact of the Dose of Post-Transplant Cyclophosphamide and the Start Timing of Tacrolimus in Patients Who Received Allogeneic Stem-Cell Transplantation from Haploidentical Donor

Toshiki Terao, Ken-ichi Matsuoka, Hiroki Takasuka, Takumi Kondo, Chihiro Kamoi, Hiroko Ueda, Akifumi Matsumura, Chisato Matsubara, Kaho Kondo, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Yoshinobu Maeda

Blood (2022) 140 (Supplement 1): 12867–12868.

https://doi.org/10.1182/blood-2022-166571

Published: 2022

Journal Articles

Influence of Oral Microbiota on Chronic Graft-Versus-Host Disease and Its Role As a Therapeutic Target

Yui Kambara, Hideaki Fujiwara, Akira Yamamoto, Mari Kunihiro, Tadashi Oyama, Takumi Kondo, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Nobuharu Fujii, Keiko Fujii, Ken-ichi Matsuoka, Yoshinobu Maeda

Blood (2022) 140 (Supplement 1): 10202–10203.

https://doi.org/10.1182/blood-2022-162323

Published: 2022

Journal Articles

Gilteritinib Maintenance Therapy Post-Allogenic Stem-Cell Transplantation Improves the Prognosis of Patients with FLT3-Mutated AML

Toshiki Terao, Ken-ichi Matsuoka, Hiroko Ueda, Akifumi Matsumura, Chisato Matsubara, Kaho Kondo, Takumi Kondo, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Yoshinobu Maeda

Blood (2022) 140 (Supplement 1): 3290–3291.

https://doi.org/10.1182/blood-2022-163876

Published: 2022

Journal Articles

Immune Profiling of Diagnostic DLBCL Biopsies Dramatically Improves upon Cell-of-Origin Risk Stratification

Michael Nissen, Xuehai Wang, Clementine Sarkozy, Aixiang Jiang, Daisuke Ennishi, Tomohiro Aoki, Stacy Hung, Elizabeth Chavez, Jeffrey W Craig, Pedro Farinha, Graham W. Slack, David W. Scott, Christian Steidl, Andrew P. Weng

Blood (2021) 138 (Supplement 1): 719.

https://doi.org/10.1182/blood-2021-154082

Published: 2021

Journal Articles

Characterization of DLBCL with a PMBL gene expression signature

Blood (2021) 138 (2): 136–148.

https://doi.org/10.1182/blood.2020007683

Published: 2021

Includes: Supplemental data

Journal Articles

The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC

Blood (2021) 137 (16): 2196–2208.

https://doi.org/10.1182/blood.2020007193

Published: 2021

Includes: Supplemental data

Journal Articles

The Tumor Associated Antigen PRAME Exhibits Dualistic Functions That Are Targetable in Diffuse Large B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-141168

Published: 2020

Journal Articles

Favorable Outcomes of Newly Diagnosed Intravascular Large B-Cell Lymphoma Patients Treated with R-CHOP Combined with High-Dose Methotrexate Plus Intrathecal Chemotherapy: Results from a Multicenter Phase 2 Trial (PRIMEUR-IVL)

Blood (2019) 134 (Supplement_1): 350.

https://doi.org/10.1182/blood-2019-126798

Published: 2019

Journal Articles

TP53 Expression Correlates with TP53 Mutations and Is an Independent Predictor of Clinical Outcome in Patients with DLBCL Treated with R-CHOP

Pedro Farinha, MD PhD, Daisuke Ennishi, MD PhD, Anja Mottok, MD PhD, Susana Ben-Neriah, BSc, Barbara Meissner, PhD, Merrill Boyle, BSc, Jeffrey W. Craig, MD PhD, Graham W Slack, MD, Diego Villa, MD MPH, Kerry J Savage, BSc, MD MSc, Laurie H Sehn, MD, Ryan D. Morin, PhD, Marco A. Marra, PhD, Joseph M. Connors, MD, Randy D. Gascoyne, MD, Christian Steidl, MD, David W. Scott, MBChB, PhD

Blood (2019) 134 (Supplement_1): 3964.

https://doi.org/10.1182/blood-2019-121943

Published: 2019

Journal Articles

Molecular Correlates of Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma

Robert Kridel, MDMPH,PhD, Keren Isaev, MSc, Daisuke Ennishi, MD PhD, Brian Skinnider, MD, Karen Mungall, PhD, Andrew J. Mungall, PhD, Mehran Bakhtiari, MSc, Rosemarie Tremblay-Lemay, MD MSc, FRCPC, Barbara Meissner, PhD, Susana Ben-Neriah, BSc, Merrill Boyle, BSc, Diego Villa, MD MPH, Marco A. Marra, PhD, Christian Steidl, MD, Randy D. Gascoyne, MD, Kerry J Savage, BSc, MD MSc, David W. Scott, MBChB, PhD

Blood (2019) 134 (Supplement_1): 2763.

https://doi.org/10.1182/blood-2019-124235

Published: 2019

Journal Articles

Diffuse Large B-Cell Lymphomas with a Molecular PMBCL Expression Signature Represent a Distinct Molecular Subtype Associated with Poor Clinical Outcome

Gerben Duns, PhD, Elena Viganò, PhD, Daisuke Ennishi, MD PhD, Clementine Sarkozy, MD, Stacy Hung, Elizabeth Chavez, Katsuyoshi Takata, MD PhD, Anja Mottok, MD PhD, Randy D. Gascoyne, MD, Ryan D. Morin, PhD, Kerry J Savage, BSc, MD MSc, David W. Scott, MBChB, PhD, Christian Steidl, MD

Blood (2019) 134 (Supplement_1): 922.

https://doi.org/10.1182/blood-2019-131450

Published: 2019

Journal Articles

The Double-Hit Gene Expression Signature Defines a Clinically and Biologically Distinct Subgroup within GCB-DLBCL

Blood (2018) 132 (Supplement 1): 921.

https://doi.org/10.1182/blood-2018-99-116827

Published: 2018

Journal Articles

Somatic PRAME Deletions Are Associated with Decreased Immunogenicity, Apoptosis Resistance and Poor Outcomes in Diffuse Large B-Cell Lymphoma

Katsuyoshi Takata, MD PhD, Daisuke Ennishi, MDPhD, Ali Bashashati, Saeed Saberi, Elena Viganò, PhD, Shannon Healy, PhD, Julie S Nielsen, Gianluca D' Antonio, Brad H Nelson, Sohrab P Shah, Joseph M Connors, Randy D. Gascoyne, MD, David W. Scott, PhDMD,FRACP,FRCPA, Christian Steidl, MD

Blood (2018) 132 (Supplement 1): 667.

https://doi.org/10.1182/blood-2018-99-113516

Published: 2018

Journal Articles

Recurrent IL4R Somatic Mutations in Diffuse Large B-Cell Lymphoma Lead to an Altered Gene Expression Profile and Changes in Tumor Microenvironment Composition

Elena Viganò, PhD, Gerben Duns, PhD, Daisuke Ennishi, MDPhD, Randy D. Gascoyne, MD, Ryan D. Morin, PhDBSc,MSc, David W. Scott, PhDMD,FRACP,FRCPA, Christian Steidl, MD

Blood (2018) 132 (Supplement 1): 669.

https://doi.org/10.1182/blood-2018-99-110473

Published: 2018

Journal Articles

Efficacy of HLA-Matched PLT Transfusions for Platelet Transfusion Refractoriness in HSCT Patients

Keisuke Seike, Nobuharu Fujii, MD PhD, Keiko Fujii, MD PhD, Yasuhisa Sando, MD, Makoto Nakamura, MD, Kyosuke Saeki, MD, Yusuke Meguri, MD, Noboru Asada, MD PhD, Daisuke Ennishi, MDPhD, Hisakazu Nishimori, MD PhD, Ken-Ichi Matsuoka, MD PhD, Yoshinobu Maeda, MDPhD

Blood (2018) 132 (Supplement 1): 1265.

https://doi.org/10.1182/blood-2018-99-112365

Published: 2018

Journal Articles

Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 As a Therapeutic Target for Restoring MHC Expression in Diffuse Large B-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 1560.

https://doi.org/10.1182/blood-2018-99-112010

Published: 2018

NARROW

CD79 Expression Is Associated with Cell-of-Origin and Outcome in Diffuse Large B-Cell Lymphoma

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study

Single Cell Multi Omics and Spatial Analysis Reveals Plasmablast Signature Malignant Cells As a Key of Intratumor Heterogeneity in Primary Central Nervous System Lymphoma

Clinical Impact of Cell-of-Origin and Double-Hit Signature of DLBCL in Japan

Impact of the Dose of Post-Transplant Cyclophosphamide and the Start Timing of Tacrolimus in Patients Who Received Allogeneic Stem-Cell Transplantation from Haploidentical Donor

Influence of Oral Microbiota on Chronic Graft-Versus-Host Disease and Its Role As a Therapeutic Target

Gilteritinib Maintenance Therapy Post-Allogenic Stem-Cell Transplantation Improves the Prognosis of Patients with FLT3-Mutated AML

Immune Profiling of Diagnostic DLBCL Biopsies Dramatically Improves upon Cell-of-Origin Risk Stratification

Characterization of DLBCL with a PMBL gene expression signature

The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC

The Tumor Associated Antigen PRAME Exhibits Dualistic Functions That Are Targetable in Diffuse Large B-Cell Lymphoma

Favorable Outcomes of Newly Diagnosed Intravascular Large B-Cell Lymphoma Patients Treated with R-CHOP Combined with High-Dose Methotrexate Plus Intrathecal Chemotherapy: Results from a Multicenter Phase 2 Trial (PRIMEUR-IVL)

TP53 Expression Correlates with TP53 Mutations and Is an Independent Predictor of Clinical Outcome in Patients with DLBCL Treated with R-CHOP

Molecular Correlates of Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphomas with a Molecular PMBCL Expression Signature Represent a Distinct Molecular Subtype Associated with Poor Clinical Outcome

The Double-Hit Gene Expression Signature Defines a Clinically and Biologically Distinct Subgroup within GCB-DLBCL

Somatic PRAME Deletions Are Associated with Decreased Immunogenicity, Apoptosis Resistance and Poor Outcomes in Diffuse Large B-Cell Lymphoma

Recurrent IL4R Somatic Mutations in Diffuse Large B-Cell Lymphoma Lead to an Altered Gene Expression Profile and Changes in Tumor Microenvironment Composition

Efficacy of HLA-Matched PLT Transfusions for Platelet Transfusion Refractoriness in HSCT Patients

Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 As a Therapeutic Target for Restoring MHC Expression in Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only